6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 10▼ RSI OverboughtRSI 100.0, above 70, stock may be overbought
Jul 9CONFIRMED▲ Above MA150+0.1% from MA150, price crossed above
▲ Above MA200+0.4% from MA200, price crossed above
▲ RSI OversoldRSI 0.0, below 30, stock may be oversold
About Drugs Made In America Acquisition Corp.
Part of the financial services sector, Drugs Made In America Acquisition Corp. (DMAAU) is listed under Shell Companies. does not have significant operations.
Premium feature
News & analytics is part of Premium.
Every headline runs through our finance-grade sentiment engine, so you see the mood of the market on each ticker before you read a single article. Plus the full analyst consensus and target-price upside, refreshed daily.
Per-headline sentiment, scored by a finance-tuned model
See exactly where the price sits versus its 150-day moving average, the live RSI reading, MACD momentum, and volume context, for any ticker, every day.
Where DMAAU stands vs its 150-day and 200-day moving averages
As of the July 10, 2026 close, DMAAU finished 1.13% above its 150-day moving average ($10.60) and 1.42% above its 200-day moving average ($10.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DMAAU overbought or oversold?
At the July 10, 2026 close, DMAAU's RSI(14) was 100.0, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Key stats
52W Change+5.3%
Analysis
The company holds $15K in cash, though total debt stands at $100K. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Drugs Made In America Acquisition Corp. and its sector.
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
DMAAU: Drugs Made In America Acquisition Corp. Technical Analysis (200-Day MA, RSI, MACD) | Scanance